PEDIATRIC INVESTIGATION PRACTICE
GUIDELINES AND POLICIES 2025 FINAL
COMPREHENSIVE ASSESSMENT TEST
PAPER QUESTIONS AND SOLUTIONS
⩥ What challenges do multiregional pediatric drug development
programs face?
Answer: Regional differences in regulatory requirements and standards
of care.
⩥ What should be considered regarding medical need in pediatric
populations?
Answer: What medical need the drug could address in one or more
pediatric populations.
⩥ What is a key question regarding pediatric populations in drug
development?
Answer: Who are the appropriate pediatric populations or subgroups that
could be considered?
⩥ What should be addressed based on the intended pediatric use of the
drug?
Answer: Key issues in the drug development program.
,⩥ What knowledge gaps should be addressed for safe and effective drug
use?
Answer: Gaps based on existing knowledge, including developmental
physiology and disease pathophysiology.
⩥ What should be considered for specific pediatric subgroups?
Answer: Different formulations, dosage forms, or delivery devices.
⩥ What is the role of stakeholders in pediatric drug development?
Answer: To provide input based on scientific advances and up-to-date
knowledge.
⩥ What is essential for agreement on a pediatric development program?
Answer: Early consideration of pediatric populations and interactions
with regulatory authorities.
⩥ What does Section 5 of the addendum focus on?
Answer: Approaches to optimize pediatric drug development, including
modeling and simulation.
⩥ What does Section 6 discuss in the context of pediatric clinical trials?
Answer: Practicalities in the design and execution of trials, including
feasibility and outcome assessments.
, ⩥ What is the significance of minimizing the burden of trial-related
activities?
Answer: To ensure that the participation of pediatric subjects is as low-
risk as possible.
⩥ What is the overarching goal of the ICH E11 addendum?
Answer: To ensure timely access to medicines for children by
harmonizing pediatric drug development.
⩥ What is emphasized about the ethical conduct of pediatric studies?
Answer: The roles and responsibilities of the IRB/IEC and the
recruitment of study participants.
⩥ What must be provided to parents and child participants during
enrollment?
Answer: Clear information regarding participation and the consent
process.
⩥ What is the purpose of Section 4 in the ICH E11 addendum?
Answer: To address age classification and pediatric subgroups, including
neonates.
⩥ What is the focus of Section 3 in the addendum?
GUIDELINES AND POLICIES 2025 FINAL
COMPREHENSIVE ASSESSMENT TEST
PAPER QUESTIONS AND SOLUTIONS
⩥ What challenges do multiregional pediatric drug development
programs face?
Answer: Regional differences in regulatory requirements and standards
of care.
⩥ What should be considered regarding medical need in pediatric
populations?
Answer: What medical need the drug could address in one or more
pediatric populations.
⩥ What is a key question regarding pediatric populations in drug
development?
Answer: Who are the appropriate pediatric populations or subgroups that
could be considered?
⩥ What should be addressed based on the intended pediatric use of the
drug?
Answer: Key issues in the drug development program.
,⩥ What knowledge gaps should be addressed for safe and effective drug
use?
Answer: Gaps based on existing knowledge, including developmental
physiology and disease pathophysiology.
⩥ What should be considered for specific pediatric subgroups?
Answer: Different formulations, dosage forms, or delivery devices.
⩥ What is the role of stakeholders in pediatric drug development?
Answer: To provide input based on scientific advances and up-to-date
knowledge.
⩥ What is essential for agreement on a pediatric development program?
Answer: Early consideration of pediatric populations and interactions
with regulatory authorities.
⩥ What does Section 5 of the addendum focus on?
Answer: Approaches to optimize pediatric drug development, including
modeling and simulation.
⩥ What does Section 6 discuss in the context of pediatric clinical trials?
Answer: Practicalities in the design and execution of trials, including
feasibility and outcome assessments.
, ⩥ What is the significance of minimizing the burden of trial-related
activities?
Answer: To ensure that the participation of pediatric subjects is as low-
risk as possible.
⩥ What is the overarching goal of the ICH E11 addendum?
Answer: To ensure timely access to medicines for children by
harmonizing pediatric drug development.
⩥ What is emphasized about the ethical conduct of pediatric studies?
Answer: The roles and responsibilities of the IRB/IEC and the
recruitment of study participants.
⩥ What must be provided to parents and child participants during
enrollment?
Answer: Clear information regarding participation and the consent
process.
⩥ What is the purpose of Section 4 in the ICH E11 addendum?
Answer: To address age classification and pediatric subgroups, including
neonates.
⩥ What is the focus of Section 3 in the addendum?
